Literature DB >> 8912852

Gangliosides expressed in human breast cancer.

G Marquina1, H Waki, L E Fernandez, K Kon, A Carr, O Valiente, R Perez, S Ando.   

Abstract

Breast tumors that were histopathologically diagnosed as invasive ductal carcinoma were examined in relation to their abnormal expression of gangliosides. Total ganglioside levels that were expressed as lipid-bound sialic acids were significantly higher in breast tumor tissues than in normal mammary tissues. Two kinds of unusual gangliosides were found to be expressed in many cases of breast tumors. One was a group of O-acetylated gangliosides, such as O-acetyl-GD3 and O-acetyl-GT3. They are known as fetal gangliosides, which appear in fetal brains. The other was an N-glycolylneuraminic acid-containing ganglioside, N-glycolyl-GM3, which had not been previously found in normal human tissues. The finding that unusual gangliosides are expressed in breast tumors may provide the basis for their immunological diagnosis and vaccine therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912852

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  73 in total

1.  Total synthesis of a cholinergic neuron-specific ganglioside GT1a alpha: a high affinity ligand for myelin-associated glycoprotein (MAG).

Authors:  H Ito; H Ishida; H Waki; S Ando; M Kiso
Journal:  Glycoconj J       Date:  1999-10       Impact factor: 2.916

2.  Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer.

Authors:  Brian M Kennedy; Randall E Harris
Journal:  Inflammopharmacology       Date:  2018-05-07       Impact factor: 4.473

3.  Breast Tumor-Associated Metalloproteases Restrict Reovirus Oncolysis by Cleaving the σ1 Cell Attachment Protein and Can Be Overcome by Mutation of σ1.

Authors:  Jason P Fernandes; Francisca Cristi; Heather E Eaton; Patricia Chen; Sarah Haeflinger; Isabelle Bernard; Mary M Hitt; Maya Shmulevitz
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

4.  Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.

Authors:  G M Piperno; A López-Requena; A Predonzani; D Dorvignit; M Labrada; L Zentilin; O R Burrone; M Cesco-Gaspere
Journal:  Gene Ther       Date:  2015-07-16       Impact factor: 5.250

5.  Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker.

Authors:  Qinying Li; Mei Sun; Mingsheng Yu; Qianyun Fu; Hao Jiang; Guangli Yu; Guoyun Li
Journal:  Glycoconj J       Date:  2019-07-11       Impact factor: 2.916

6.  The HMW2 adhesin of non-typeable Haemophilus influenzae is a human-adapted lectin that mediates high-affinity binding to 2-6 linked N-acetylneuraminic acid glycans.

Authors:  John M Atack; Christopher J Day; Jessica Poole; Kenneth L Brockman; Lauren O Bakaletz; Stephen J Barenkamp; Michael P Jennings
Journal:  Biochem Biophys Res Commun       Date:  2018-06-27       Impact factor: 3.575

Review 7.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

8.  High level of sialate-O-acetyltransferase activity in lymphoblasts of childhood acute lymphoblastic leukaemia (ALL): enzyme characterization and correlation with disease status.

Authors:  Chandan Mandal; G Vinayaga Srinivasan; Suchandra Chowdhury; Sarmila Chandra; Chhabinath Mandal; Roland Schauer; Chitra Mandal
Journal:  Glycoconj J       Date:  2008-08-03       Impact factor: 2.916

Review 9.  Tumour-associated carbohydrate antigens in breast cancer.

Authors:  Aurélie Cazet; Sylvain Julien; Marie Bobowski; Joy Burchell; Philippe Delannoy
Journal:  Breast Cancer Res       Date:  2010-06-08       Impact factor: 6.466

Review 10.  NGcGM3/VSSP vaccine as treatment for melanoma patients.

Authors:  Kirenia Pérez; Marta Osorio; Julio Hernández; Adriana Carr; Luis Enrique Fernández
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.